Lucid Diagnostics INC

Lucid Diagnostics stockholders approved the re-election of directors and an increase in authorized common stock to 400 million shares.

Lucid Diagnostics reported $1.3 million in Q1 2026 revenue from 3,177 EsoGuard tests, bolstered by a $17 million stock offering, extending its cash runway into 2027.

Lucid Diagnostics has successfully closed an underwritten public offering of 18 million shares at $1.00 per share, raising approximately $16.8 million in net proceeds.

Lucid Diagnostics has priced an underwritten public offering of 18 million shares of common stock at $1.00 per share to raise $18 million in gross proceeds.

Lucid Diagnostics announced its fourth quarter and full year 2025 financial results, reporting $1.5 million in Q4 revenue and a significant contract award with the U.S. Department of Veterans Affairs.

Lucid Diagnostics announced its third-quarter 2025 financial results, reporting $1.2 million in EsoGuard revenue and significant progress towards Medicare coverage for its EsoGuard test.

Lucid Diagnostics reports increased revenue in Q1 2026, but net loss widens due to higher operating expenses and changes in convertible note valuation.

Lucid Diagnostics reports a slight revenue increase and significantly boosted cash reserves from recent offerings, but continues to face substantial doubt about its ability to continue as a going concern.

Lucid Diagnostics Inc. reported a significantly increased net loss for the first half of 2025, despite a stronger cash position from recent capital raises and progress in commercializing its EsoGuard test.

Lucid Diagnostics reports a net loss of $26.9 million for Q1 2025, while focusing on securing Medicare coverage for its EsoGuard test and highlighting a recent NCCN guidelines update.

Lucid Diagnostics saw revenue increase in Q3 2024 compared to the same period last year, but also experienced a net loss due to higher operating expenses and debt-related costs.

Lucid Diagnostics saw a significant increase in revenue in the second quarter of 2024, but ongoing losses and cash burn raise concerns about its ability to continue as a going concern.

Lucid Diagnostics' 2025 annual report details revenue growth, significant capital raises, and key product advancements, alongside persistent operating losses and substantial doubt about its ability to continue as a going concern.

Lucid Diagnostics' 10-K filing details its financial position, including ongoing losses and efforts to secure Medicare coverage for its EsoGuard test amid evolving regulatory landscapes.

Lucid Diagnostics' 10-K filing outlines its share structure, recent preferred stock offerings, and various agreements with PAVmed, its parent company.

Lucid Diagnostics Inc. reports a significant stock purchase by Director Dennis Matheis, acquiring 245,000 shares.

Lucid Diagnostics CEO Lishan Aklog received a grant of 2.17 million restricted common stock shares, vesting in 2029.

Lucid Diagnostics director Dennis Matheis was granted 123,000 shares of restricted common stock, vesting in May 2029.

Lucid Diagnostics Inc. director Debra White was granted 123,000 shares of common stock, vesting in 2029, under the company's 2018 Equity Plan.

Lucid Diagnostics Inc. director Ronald M. Sparks was granted 123,000 restricted common shares vesting in 2029.

Lucid Diagnostics Inc. Director Jacque J. Sokolov was granted 123,000 shares of restricted common stock, vesting in May 2029.

Lucid Diagnostics Inc. has filed its proxy statement for the 2026 Annual Meeting, seeking approval for a capital increase and director elections.

Lucid Diagnostics Inc. has filed a definitive proxy statement with the SEC.

Lucid Diagnostics Inc. will hold its annual meeting on June 18, 2025, to vote on director elections, approve a stock issuance related to convertible notes, and ratify the appointment of its accounting firm.

Lucid Diagnostics has rescheduled its annual meeting to July 23, 2024, to modify proposals including stock issuance approval and an increase in authorized common stock.

Lucid Diagnostics Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Lucid Diagnostics Inc. has rescheduled its 2024 annual meeting of stockholders from June 20, 2024, to July 23, 2024, to modify the proposals to be voted upon.

PAVmed Inc. filed an Amendment No. 6 to its Schedule 13D, detailing updated beneficial ownership in Lucid Diagnostics Inc. and new agreements solidifying its influence as the parent company.

PAVmed Inc. has increased its beneficial ownership in Lucid Diagnostics Inc. to 28.3% through recent stock awards and voting agreements, solidifying its influence as the parent company.

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC, and Waqas Khatri have jointly disclosed a 2.0% beneficial ownership stake in Lucid Diagnostics Inc. as of December 31, 2024.